NCCN: National Comprehensive Cancer Network Annual Conference

Dr Toby Campbell Outlines the Importance of Early End-of-Life Care Discussions

March 25, 2019

The move to value-based care has increased the use of palliative care, and new research has found that conversations about end-of-life care should be happening earlier, said Toby C. Campbell, MD, MSCI, of the University of Wisconsin Carbone Cancer Center.

NCCN Ovarian Cancer Guidelines Add Options for PARP Inhibitors, Bevacizumab

March 25, 2019

A presentation Saturday at the National Comprehensive Cancer Network Annual Conference in Orlando, Florida, outlined several key updates for treatment in ovarian cancer based on new studies and approvals for poly (ADP-ribose) polymerase (PARP) inhibitors and bevacizumab.

Dr David M. O'Malley on Identifying Which Patients Will Respond to PARP Inhibitors

March 24, 2019

We're getting better at identifying which patients with ovarian cancer will respond to poly ADP-ribose polymerase (PARP) inhibitors, but we have a long way to go, said David M. O'Malley, MD, professor of medicine, Department of Gynecology, and director of Gynecologic Oncology Clinical Research at the James Cancer Center, Ohio State University.

Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved

March 24, 2019

Although there is still a need for more education around the use of biosimilars in cancer, it seems oncologists have become more knowledgeable in the past few years, said Gary H. Lyman, MD, MPH, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance.

The Art and Science of Talking About End-of-Life Care

March 24, 2019

On the last day of the 2019 National Comprehensive Cancer Network Annual Conference, a thoracic oncologist and palliative care physician shared strategies and specific phrases for guiding end-of-life discussions that have been developed, tested, and studied at the University of Wisconsin.

Aging Population, Rising Morbidity Add to Challenge of Survivorship

March 23, 2019

As more cancer survivors live longer, the challenges increase for those responsible for coordinating care among primary care providers, specialists, and oncologists. The concept of survivorship continues to evolve to include life long after cancer treatment, according to updated guidelines from the National Comprehensive Cancer Network.

NCCN Prostate Cancer Update Emphasizes Germline Testing

March 22, 2019

Germline testing at diagnosis, along with tumor testing, have the potential to identify candidates for investigational poly (ADP-ribose) polymerase (PARP) inhibitors, and updated guidelines call for their expanded use.

Dr John Ward on Conversations With Patients After Multigene Testing

March 22, 2019

Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.

Dr John Sweetenham Discusses the Impact of CMS' Proposal on Access to CAR T-Cell Therapies

March 22, 2019

CMS’ proposal that patients be enrolled in a clinical trial or registry to get Medicare coverage for chimeric antigen receptor (CAR) T-cell therapies will help improve access, for the most part, but there is the risk that some organizations will choose not to offer this treatment, said John W. Sweetenham, MD, of Huntsman Cancer Institute at the University of Utah.